Vivimed Labs Hits Lower Circuit Amid Heavy Selling Pressure and Panic Selling

Intraday Price Movement and Circuit Breaker Activation

On the trading day, Vivimed Labs opened sharply lower, reflecting a gap down of 5.0% from its previous close. The stock price immediately touched the lower circuit price band of ₹22.81 and remained locked at this level throughout the session. This lack of price movement beyond the circuit limit indicates that selling interest overwhelmed buying demand, triggering the automatic trading halt mechanism designed to curb excessive volatility.

The stock’s high and low price for the day were both recorded at ₹22.81, confirming that no trades occurred outside the lower circuit band. Such a scenario is indicative of panic selling, where sellers aggressively offload shares, but buyers are either absent or unwilling to transact at prevailing prices.

Trading Volume and Liquidity Analysis

Trading volumes for Vivimed Labs were notably thin, with a total traded volume of just 0.00022 lakh shares, translating to a turnover of approximately ₹5,018. This extremely low liquidity suggests that despite the heavy selling pressure, the stock struggled to find sufficient buyers, resulting in unfilled supply and a persistent downward price lock.

Further emphasising the subdued investor participation, the delivery volume on 22 Dec 2025 was recorded at 2,330 shares, which is a steep decline of 86.96% compared to the five-day average delivery volume. This drop in delivery volume signals a waning commitment from investors to hold the stock amid the ongoing price weakness.

Comparative Performance and Market Context

Vivimed Labs underperformed its sector by 4.95% on the day, while the broader Sensex index registered a marginal decline of 0.19%. The sector itself showed a slight positive return of 0.02%, highlighting that the stock’s sharp fall was not reflective of broader market or sector trends but rather company-specific factors or sentiment.

Despite the current price weakness, it is noteworthy that Vivimed Labs is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This technical detail suggests that the recent price drop is an abrupt deviation from its longer-term price trends, possibly driven by short-term market dynamics or news flow.

Market Capitalisation and Company Profile

Vivimed Labs is classified as a micro-cap company with a market capitalisation of approximately ₹189.13 crore. Operating within the Pharmaceuticals & Drugs industry, the company’s stock is listed under the BE series. The micro-cap status often entails higher volatility and lower liquidity, which can exacerbate price movements during periods of intense selling or market uncertainty.

The stock’s recent trading pattern, including erratic sessions where it did not trade on one day out of the last 20, further underscores the challenges faced by investors in maintaining consistent market participation.

Investor Sentiment and Potential Implications

The sharp fall and circuit lock at the lower price band reflect a pronounced negative sentiment among investors. Panic selling often arises from concerns over company fundamentals, sector outlook, or broader market fears. The unfilled supply at the lower circuit price suggests that sellers were eager to exit positions, but buyers remained cautious, possibly awaiting clearer signals before re-entering.

Such market behaviour can lead to increased volatility in subsequent sessions as investors reassess valuations and risk. For Vivimed Labs, the current price action may prompt closer scrutiny from market participants regarding the company’s operational performance and future prospects.

Technical Indicators and Moving Averages

Despite the day’s negative price action, Vivimed Labs remains positioned above its key moving averages across multiple timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates that the stock’s recent decline is a short-term aberration rather than a sustained downtrend.

Investors often view such moving averages as dynamic support levels, and a breach below these could signal further weakness. For now, the stock’s price being locked at the lower circuit suggests a pause in trading activity, with market participants likely awaiting fresh developments or confirmation of the company’s outlook.

Outlook and Considerations for Investors

Given the micro-cap nature of Vivimed Labs and the recent trading volatility, investors should exercise caution and closely monitor forthcoming corporate announcements, sector developments, and broader market conditions. The current episode of panic selling and circuit lock highlights the risks associated with low liquidity stocks, where price swings can be amplified.

Market participants may also consider the company’s fundamentals and valuation metrics in the context of the Pharmaceuticals & Drugs industry to better understand the underlying factors influencing the stock’s performance.

Summary

Vivimed Labs’ stock hitting the lower circuit at ₹22.81 on 23 Dec 2025, with a maximum daily loss of 5.0%, underscores the heavy selling pressure and panic selling that characterised the session. The extremely low traded volume and delivery participation reflect a lack of buyer interest, resulting in unfilled supply and a locked price band. While the stock remains above key moving averages, the current market sentiment signals caution for investors navigating this micro-cap pharmaceutical stock.

Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Claim Your Free Year →